{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-26-000051","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.112695+00:00","generated_at":"2026-05-16T11:03:03.284308+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"confidence":"high","headline":"Cartesian updates Descartes-08 pipeline; IND accepted in myositis, pediatric trial initiated","bullets":["Phase 3 AURORA trial for Descartes-08 in myasthenia gravis enrollment on track; data expected to support cash runway into mid-2027.","FDA accepted IND for Descartes-08 in myositis; seamless adaptive Phase 2 TRITON trial expected to start 1H26.","Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis initiated.","Two Nature Medicine publications; Phase 2b MG data showed 55% median prednisone dose reduction at Month 12, no CRS or ICANS.","Cash resources expected to fund operations including Phase 3 trial completion through mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-26-000051","json":"https://secwatch.observer/filing/0001453687-26-000051.json","markdown":"https://secwatch.observer/filing/0001453687-26-000051.md","text":"https://secwatch.observer/filing/0001453687-26-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000051/0001453687-26-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000051/rnac-20260109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:03:03.284308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}